Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trazodone Hydrochloride

FDA-approved product (tablet, oral), marketed as Desyrel, Oleptro, Raldesy and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Trazodone Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Major depressive disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antidepressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA42.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli43.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trazodone Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.7 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trazodone Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • RCT: Trazodone vs Quetiapine vs Placebo for Treating ICU Delirium (TraQ)

    NCT05085808 · start 2028-03-01

    Registered record
    Registry ID
    NCT05085808
    Conditions
    Delirium; Morality; Quality of Life; Psych; Treatment Side Effects
    Interventions
    Trazodone; Quetiapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2028-03-01
    Completion
    2030-12-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium; Morality; Quality of Life; Psych +1 more
    InterventionTrazodone; Quetiapine; Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)

    NCT07210112 · start 2026-06-30

    Registered record
    Registry ID
    NCT07210112
    Conditions
    Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD)
    Interventions
    Psilocybin 25 mg per os; Trazodone 5mg; Trazodone 30 mg; Placebo of psilocybin; Placebo of trazodone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-06-30
    Completion
    2030-06-30
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepression - Major Depressive Disorder; Treatment-resistant Depression (TRD)
    InterventionPsilocybin 25 mg per os; Trazodone 5mg; Trazodone 30 mg; Placebo of psilocybin +1 more
    PhasePhase 2
    Registry statusRecruiting

  • A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia

    NCT07542756 · start 2026-05-01

    Registered record
    Registry ID
    NCT07542756
    Conditions
    Insomnia; Insomnia Disorder; Chronic Insomnia; Chronic Insomnia Disorder
    Interventions
    Sleep Hygiene Education; Melatonin IR, 3 mg; Melatonin IR, 5 mg; Diphenhydramine, 25 mg; Diphenhydramine, 50 mg; Doxepin, 3 mg; Doxepin, 6 mg; Trazodone, 50 mg; Trazodone, 100 mg; Placebo; Zolpidem, 5 mg; Zolpidem, 10 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-05-01
    Completion
    2032-01-01
    Enrolment
    1,200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInsomnia; Insomnia Disorder; Chronic Insomnia; Chronic Insomnia Disorder
    InterventionSleep Hygiene Education; Melatonin IR, 3 mg; Melatonin IR, 5 mg; Diphenhydramine, 25 mg +8 more
    PhasePhase 4
    Registry statusRecruiting

  • Comparing Acupuncture With Medication to Reduce Depression, Anxiety and Comorbid Sleep Disorders in China

    NCT07552246 · start 2026-04-01

    Registered record
    Registry ID
    NCT07552246
    Conditions
    Anxiety Depression; Sleep
    Interventions
    Psychotropic Drugs; Acupuncture
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-04-01
    Completion
    2027-12-31
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnxiety Depression; Sleep
    InterventionPsychotropic Drugs; Acupuncture
    PhasePhase 4
    Registry statusRecruiting

  • Standardized Sleep Bundle for Cardiac Surgery Patients

    NCT07401836 · start 2026-03-02

    Registered record
    Registry ID
    NCT07401836
    Conditions
    Sleep
    Interventions
    Standardized Sleep Protocol; Usual Post Operative Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2026-03-02
    Completion
    2026-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep
    InterventionStandardized Sleep Protocol; Usual Post Operative Care
    PhaseNot applicable
    Registry statusRecruiting

  • Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms

    NCT07136415 · start 2026-02-13

    Registered record
    Registry ID
    NCT07136415
    Conditions
    Menopausal Women; Insomnia
    Interventions
    Cognitive behavioral therapy for insomnia (CBT-i); Trazodone; Daridorexant
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-02-13
    Completion
    2031-02
    Enrolment
    1,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopausal Women; Insomnia
    InterventionCognitive behavioral therapy for insomnia (CBT-i); Trazodone; Daridorexant
    PhasePhase 4
    Registry statusRecruiting

  • One-Year Study of S1B-509 vs Placebo for Weight Loss

    NCT06517797 · start 2025-10-15

    Registered record
    Registry ID
    NCT06517797
    Conditions
    Obesity
    Interventions
    S1B-509 low dose; Placebo; S1B-509 High Dose
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-10-15
    Completion
    2027-12-15
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionS1B-509 low dose; Placebo; S1B-509 High Dose
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Cohort Study on Increasing Blood Pressure Benefits in Sleep Apnea Patients After CPAP Treatment

    NCT07357272 · start 2025-09-15

    Registered record
    Registry ID
    NCT07357272
    Conditions
    Hypertension (HTN); Sleep Apnea Syndrome, Obstructive
    Interventions
    continuous positive airway pressure
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-09-15
    Completion
    2028-07-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension (HTN); Sleep Apnea Syndrome, Obstructive
    Interventioncontinuous positive airway pressure
    PhaseNot recorded
    Registry statusRecruiting

  • Pharmacological Treatment Targeting Endotypic Traits of Obstructive Sleep Apnea

    NCT06295562 · start 2024-11-05

    Registered record
    Registry ID
    NCT06295562
    Conditions
    Obstructive Sleep Apnea of Adult
    Interventions
    Atomoxetine 80mg combined with oxybutynin 5mg; Venlafaxine 37.5mg; oxybutynin 5mg combined with trazodone 100mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-11-05
    Completion
    2025-10-22
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea of Adult
    InterventionAtomoxetine 80mg combined with oxybutynin 5mg; Venlafaxine 37.5mg; oxybutynin 5mg combined with trazodone 100mg; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Quetiapine Versus Trazadone in Women With Postpartum Depression

    NCT06546358 · start 2024-09

    Registered record
    Registry ID
    NCT06546358
    Conditions
    Postpartum Depression
    Interventions
    Trazodone; Quetiapine
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2024-09
    Completion
    2025-12
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostpartum Depression
    InterventionTrazodone; Quetiapine
    PhaseEarly phase 1
    Registry statusUnknown

  • Trazodone vs. Quetiapine for the Treatment of ICU Delirium

    NCT05307003 · start 2024-06-01

    Registered record
    Registry ID
    NCT05307003
    Conditions
    Delirium; Delirium of Mixed Origin; Delirium, Sepsis Associated; Delirium in Old Age; Delirium Confusional State; Psych; Morality; Treatment Side Effects
    Interventions
    Trazodone; Quetiapine
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Terminated
    Start
    2024-06-01
    Completion
    2024-06-01
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDelirium; Delirium of Mixed Origin; Delirium, Sepsis Associated; Delirium in Old Age +4 more
    InterventionTrazodone; Quetiapine
    PhaseNot recorded
    Registry statusTerminated

  • Trazodone on OSA Endotypes

    NCT06286189 · start 2024-01-01

    Registered record
    Registry ID
    NCT06286189
    Conditions
    Obstructive Sleep Apnea
    Interventions
    Placebo oral tablet; Trazodone Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-01-01
    Completion
    2026-06-01
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionPlacebo oral tablet; Trazodone Hydrochloride
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Rescue Pharmacotherapy for OSA

    NCT05293600 · start 2023-07-01

    Registered record
    Registry ID
    NCT05293600
    Conditions
    Obstructive Sleep Apnea
    Interventions
    Placebo; Acetazolamide; Trazodone; Atomoxetine and eszopiclone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-07-01
    Completion
    2026-10-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Sleep Apnea
    InterventionPlacebo; Acetazolamide; Trazodone; Atomoxetine and eszopiclone
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone

    NCT05282550 · start 2023-02-02

    Registered record
    Registry ID
    NCT05282550
    Conditions
    AMCI - Amnestic Mild Cognitive Impairment; Sleep Disturbance
    Interventions
    Trazodone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-02-02
    Completion
    2028-06-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAMCI - Amnestic Mild Cognitive Impairment; Sleep Disturbance
    InterventionTrazodone; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Evaluation of Trazodone in OSA-MCI

    NCT05209035 · start 2022-05-10

    Registered record
    Registry ID
    NCT05209035
    Conditions
    Mild Cognitive Impairment; Obstructive Sleep Apnea
    Interventions
    Trazodone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2022-05-10
    Completion
    2026-02-28
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild Cognitive Impairment; Obstructive Sleep Apnea
    InterventionTrazodone; Placebo
    PhasePhase 4
    Registry statusActive not recruiting